Notice Regarding the Recognition of Non-operating Income
The Company (Heartseed Inc.)
A subsidy program selected under the Japan Agency for Medical Research and Development (AMED)'s "Basic Technology Development Project for the Industrialization of Regenerative Medicine and Gene Therapy," and foreign-currency-denominated assets
Finalization of the subsidy, revaluation of foreign-currency-denominated assets, and other factors
Total of 69,833 thousand yen (non-operating income), comprising subsidy income of 52,000 thousand yen, foreign exchange gains of 12,747 thousand yen, and other items
Interim accounting period of the fiscal year ending December 2026 (1 January 2026 to 30 June 2026)
There is no change to the earnings forecast announced on 15 May 2026
| Item | Details |
|---|---|
| Event name | Notice Regarding the Recognition of Non-operating Income |
| Date of occurrence | During the interim accounting period from 1 January 2026 to 30 June 2026 |
| Subject Entity | The Company (Heartseed Inc.) |
| Target Locations / Products | A subsidy program selected under the Japan Agency for Medical Research and Development (AMED)'s "Basic Technology Development Project for the Industrialization of Regenerative Medicine and Gene Therapy," and foreign-currency-denominated assets |
| Cause | Finalization of the subsidy, revaluation of foreign-currency-denominated assets, and other factors |
| Amount of Impact on Business Performance | Total of 69,833 thousand yen (non-operating income), comprising subsidy income of 52,000 thousand yen, foreign exchange gains of 12,747 thousand yen, and other items |
| Accounting period in which recognized | Interim accounting period of the fiscal year ending December 2026 (1 January 2026 to 30 June 2026) |
| Impact on Earnings Forecast | There is no change to the earnings forecast announced on 15 May 2026 |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This resulted from subsidy income of 52,000 thousand yen following the finalization of a subsidy under an AMED subsidy program, foreign exchange gains of 12,747 thousand yen arising from the revaluation of foreign-currency-denominated assets, and other items.